ArticleCancer medicine2026
Paranasal Sinus Squamous Cell Carcinoma and Adenocarcinoma: A SEER Database Analysis.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundParanasal sinus tumors are rare malignancies that are known to be aggressive with poor outcomes. Data are limited regarding factors associated with survival and prognosis. In this study, we investigated factors associated with survival for both patients with squamous cell carcinoma (SCC) and adenocarcinoma (AC).
methodsThe Surveillance, Epidemiology and End Results (SEER) data was utilized from the years 2000 to 2019. Kaplan-Meier survival analysis and Cox regression modeling were employed to evaluate the relationship between several co-variates and overall survival (OS) and disease-specific survival (DSS) among patients with SCC and AC.
resultsA total of 5276 patients with SCC and 5222 patients with AC were included. Compared to SCC patients, those with AC were younger and presented with less differentiated and more advanced tumors (p < 0.0001). The median OS for SCC was 203 months compared to the 56 months in patients with AC (p < 0.0001). Primary site, race, stage, grade, and treatment modalities utilized were significantly predictive of OS and DSS in SCC patients in univariate analysis. Among AC patients, we found stage, grade, and treatment modalities to be significantly predictive of OS and DSS in univariate analysis. For SCC, stage (p < 0.001), primary site (p < 0.001), and treatment (p < 0.001) were significant predictors of survival on multivariate analysis. Specifically, nasal SCC was found to have improved survival compared to other sites. For AC, stage (p < 0.001) and treatment (p < 0.001) were significant predictors of survival on multivariate analysis. For both SCC and AC, treatment with both radiation and surgery had improved survival compared to radiation alone (p < 0.0001).
conclusionSCC and AC of the paranasal sinus and nasal cavity portend an overall poor prognosis with limited survival. Our study effectively elucidates factors associated with survival which may be useful in treatment and counseling patients with paranasal sinus AC and SCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.